Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Nurix Therapeutics, Inc. (NRIX)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 47,040,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other diseases. Co.'s Bruton's tyrosine kinase (BTK) degrader drug candidates, NX-2127 and NX-5948, are orally available chimeric targeting molecules for the treatment of relapsed or refractory B-cell malignancies and autoimmune indications. Co.'s drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally bioavailable Casitas B-lineage lymphoma proto-oncogene B inhibitor for immuno-oncology indications.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 34,166 46,743 69,684 82,132
Total Sell Value $602,180 $716,467 $925,403 $1,081,499
Total People Sold 3 3 3 4
Total Sell Transactions 9 13 21 37
End Date 2024-04-07 2024-01-05 2023-07-07 2022-07-07

   
Records found: 184
  Page 5 of 8  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Ring Christine General Counsel   •       –      –    2021-09-10 4 AS $35.10 $71,860 D/D (2,000) 1,286     -
   Ring Christine General Counsel   •       –      –    2021-09-10 4 OE $1.86 $3,720 D/D 2,000 3,286     -
   Ring Christine General Counsel   •       –      –    2021-09-07 4 AS $35.25 $112,800 D/D (3,200) 1,286     -
   Ring Christine General Counsel   •       –      –    2021-09-07 4 OE $1.86 $5,952 D/D 3,200 4,486     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-09-07 4 AS $35.00 $56,000 D/D (1,600) 14,197     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-09-07 4 OE $7.26 $11,616 D/D 1,600 15,797     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-09-01 4 AS $32.34 $12,936 D/D (400) 14,197     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-09-01 4 OE $7.26 $2,904 D/D 400 14,597     -
   Ring Christine General Counsel   •       –      –    2021-08-10 4 AS $29.87 $35,845 D/D (1,200) 805     -
   Ring Christine General Counsel   •       –      –    2021-08-10 4 OE $1.86 $2,232 D/D 1,200 2,005     -
   Beaurang Pierre Chief Business Officer   •       –      –    2021-08-10 4 AS $29.74 $223,926 D/D (7,500) 4,330     -
   Beaurang Pierre Chief Business Officer   •       –      –    2021-08-10 4 OE $1.11 $8,325 D/D 7,500 11,830     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-08-02 4 AS $31.21 $12,484 D/D (400) 13,804     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-08-02 4 OE $7.26 $2,904 D/D 400 14,204     -
   Ring Christine General Counsel   •       –      –    2021-07-20 4 AS $27.00 $32,400 D/D (1,200) 805     -
   Ring Christine General Counsel   •       –      –    2021-07-20 4 OE $1.86 $2,232 D/D 1,200 2,005     -
   Beaurang Pierre Chief Business Officer   •       –      –    2021-07-12 4 AS $23.88 $179,419 D/D (7,500) 4,330     -
   Beaurang Pierre Chief Business Officer   •       –      –    2021-07-12 4 OE $1.11 $8,325 D/D 7,500 11,830     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-07-01 4 AS $26.76 $10,704 D/D (400) 13,804     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-07-01 4 OE $7.26 $2,904 D/D 400 14,204     -
   Beaurang Pierre Chief Business Officer   •       –      –    2021-06-10 4 AS $29.15 $220,248 D/D (7,500) 4,330     -
   Beaurang Pierre Chief Business Officer   •       –      –    2021-06-10 4 OE $1.11 $8,325 D/D 7,500 11,830     -
   Ring Christine General Counsel   •       –      –    2021-06-10 4 AS $29.18 $35,282 D/D (1,200) 805     -
   Ring Christine General Counsel   •       –      –    2021-06-10 4 OE $1.86 $2,232 D/D 1,200 2,005     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-06-01 4 AS $27.74 $11,096 D/D (400) 13,804     -
  184 Records found
  1  2  3  4  5  6  7  8   
  Page 5 of 8
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us